F. Wilhelm

发表

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.

D. Felsher, P. Greenberg, A. Fan, 2010, Leukemia research.

A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone

E. Siris, D. Eyre, F. Singer, 1995 .

Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

P. Greenberg, A. Raza, J. Holland, 2015, Hematological oncology.

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

J. Lancet, A. Raza, A. List, 2013, British journal of haematology.

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

A. Wiestner, M. Roschewski, F. Wilhelm, 2012, Leukemia.

An extended dosing regimen of epoetin alfa 60,000 units every 2 weeks in anemic patients with cancer receiving chemotherapy.

Denise Williams, F. Wilhelm, S. Gregory, 2007, Supportive cancer therapy.

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia*

D. Henry, Denise Williams, F. Wilhelm, 2006, Current medical research and opinion.

Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy

J. Glaspy, V. Moyo, M. Kamin, 2009, Cancer.

Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.

J. Glaspy, V. Moyo, M. Kamin, 2009, Cancer.

a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer

J. Roboz, H. Gretz, J. Holland, 2013 .

Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results,

J. Lancet, A. Raza, A. List, 2011 .

Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival,

P. Greenberg, A. Raza, F. Wilhelm, 2011 .

Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response

P. Greenberg, A. Raza, E. Sloand, 2010 .

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

P. Scheinberg, J. Groopman, A. Raza, 2009 .

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

P. Greenberg, W. Fantl, E. Reddy, 2009 .

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

N. Young, E. Sloand, L. Pfannes, 2008 .

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study

E. Reddy, J. Holland, F. Wilhelm, 2010 .

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

J. Hajdenberg, B. Faltas, S. Tagawa, 2016, Clinical genitourinary cancer.

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

R. Collins, P. Greenberg, G. Gaidano, 2014 .

An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy

Denise Williams, F. Wilhelm, R. Woodman, 2007, Supportive Care in Cancer.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients.

A. Raza, S. Mukherjee, A. Eisenberger, 2013 .

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

A. Jimeno, E. Lam, M. Varella‐Garcia, 2014, Clinical Cancer Research.

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

A. Jimeno, M. Varella‐Garcia, A. Tan, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

A. Jimeno, M. Varella‐Garcia, A. Tan, 2013 .

Title : The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas

A. Jimeno, M. Varella‐Garcia, A. Tan, 2013 .

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

A. Jimeno, W. Ma, A. Adjei, 2012, Clinical Cancer Research.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

A. Bardia, R. Heist, D. Camidge, 2016 .

Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

J. Berlin, A. Bardia, T. Traina, 2016 .

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

N. Young, P. Scheinberg, E. Sloand, 2012, Leukemia research.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

R. Collins, P. Greenberg, G. Gaidano, 2016, The Lancet. Oncology.

A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone.

E. Siris, D. Eyre, B. Bosco, 1995, The Journal of clinical endocrinology and metabolism.

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

J. Roboz, H. Gretz, J. Holland, 2013, American journal of cancer research.

An open-label pilot study to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 units weekly followed by 60,000 units every 2 weeks.

Denise Williams, F. Wilhelm, P. K. Reddy, 2006, Supportive cancer therapy.

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

A. Jimeno, W. Ma, A. Adjei, 2012, Clinical Cancer Research.

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

J. Berlin, A. Bardia, J. Diamond, 2015 .

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

A. Bardia, R. Heist, W. Messersmith, 2015 .

Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.

J. Berlin, A. Bardia, M. Shah, 2015 .